Globus Medical (GMED) EBITDA (2011 - 2026)

Globus Medical's EBITDA history runs 16 years deep, the most recent figure standing at $150.4 million for Q1 2026.

• Quarterly EBITDA rose 55.03% year-over-year to $150.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $533.2 million (up 109.1% YoY) and the FY2025 annual result came in at $479.8 million, up 189.06% from the prior year.
• EBITDA was $150.4 million for Q1 2026 at Globus Medical, down from $169.3 million in the prior quarter.
• Across five years, EBITDA topped out at $169.3 million in Q4 2025 and bottomed at $404000.0 in Q3 2023.
• A 5-year average of $68.1 million and a median of $59.7 million in 2022 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2023 — EBITDA plunged 99.32% — and 2024, when it soared 11805.45%.
• Globus Medical's EBITDA stood at $54.0 million in 2022, then slumped by 81.26% to $10.1 million in 2023, then soared by 495.42% to $60.3 million in 2024, then soared by 180.95% to $169.3 million in 2025, then decreased by 11.19% to $150.4 million in 2026.
• Business Quant data shows GMED's EBITDA at $150.4 million in Q1 2026, $169.3 million in Q4 2025, and $137.4 million in Q3 2025.